Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT01149850
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
    Given IV
  • temozolomide — DRUG
    Given orally
  • laboratory biomarker analysis — OTHER
    Correlative studies
  • immunohistochemistry staining method — OTHER
    Correlative studies
  • microarray analysis — GENETIC
    Correlative studies
  • DNA methylation analysis — GENETIC
    Correlative studies

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as temozolomide, also work in different ways to kill tumor cells or stop them from growing. Giving bevacizumab together with temozolomide may be a better way to block tumor growth. PURPOSE: This phase II trial is studying how well giving bevacizumab and temozolomide together works in treating older patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Key Dates

First listed
Jun 24, 2010
Start date
Apr 28, 2010
Status verified
Feb 2024
Primary completion
Dec 8, 2023
Completion
Dec 8, 2023

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm I
    Patients receive bevacizumab IV over 30-90 minutes every 2 weeks and oral temozolomide on days 1-5. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall survival [ Time Frame: 2 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
Kaiser Foundation HospitalLos AngelesCalifornia90027-
University of California, Los AngelesLos AngelesCalifornia90095-
Kaiser Permanente at San DiegoSan DiegoCalifornia92120-

Find similar trials in Los Angeles, CA

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
Kaiser Foundation Hospital· Los Angeles, CAUniversity of California, Los Angeles· Los Angeles, CAKaiser Permanente at San Diego· San Diego, CA

Related Studies